poisar

Stocks · News reference

BTIG Reiterates Buy on BrightSpring Health, Maintains $90 Price Target

Benzinga Newsdesk

BTIG analyst David Larsen reiterates BrightSpring Health (NASDAQ:BTSG) with a Buy and maintains $90 price target.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

BTSG
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    BTSG Faces $200M IRA Hit but Efficiency May Protect Profitability

    BrightSpring Health Services' Home and Community Pharmacy segment experienced an 8% revenue decline to $540M in Q2, with the Inflation Reduction Act (IRA) accounting for approximately $50M of the impact. Despite a projected $200M revenue headwind in 2026 from IRA pricing changes, the company expects only a $15M EBITDA impact, demonstrating that operational efficiency gains from technology, automation, AI, and Lean initiatives are offsetting regulatory pressures. Peer companies Cardinal Health and CVS Health are similarly navigating IRA-driven revenue pressures while maintaining profitability through service agreements and operational improvements.

    BTSGBTSGUCAHCVS
  2. Na

    Can CAH Navigate IRA Pricing Changes Risk Without Margin Pressure?

    Cardinal Health expects fiscal 2027 IRA pricing changes to create similar revenue headwinds as 2026, but management aims to preserve compensation and maintain profitability through distribution agreements and operational efficiency. Peers BrightSpring and CVS Health also face IRA-related revenue pressure but are offsetting impacts through operational improvements and specialty pharmacy growth.

    CAHBTSGBTSGUCVS
  3. Na

    IQVIA Stock Rises 60% in 6 Months: Here's What You Should Know

    IQVIA (IQV) has surged 60.1% over six months, driven by 6% organic growth in Q2 2026, with R&DS bookings up 19.3% and a $34.2 billion backlog. The company's rapid AI adoption—294 agents deployed across 90 use cases with 19 of top 20 pharma companies adopting solutions—is strengthening its competitive position and supporting sustained growth.

    IQVBTSGBTSGUCNC
  4. Na

    Here's Why You Should Add BrightSpring Stock to Your Portfolio Now

    BrightSpring Health Services (BTSG) is rated a Strong Buy with strong momentum in Provider Services and expanding specialty pharmacy and infusion operations. However, the company faces near-term margin pressure from Inflation Reduction Act reimbursement cuts and execution risks from multiple integrations and geographic expansions through 2026.

    BTSGBTSGUVCYTGMEDWST